SAN
DIEGO, Dec. 12, 2022 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq:
RGLS), a biopharmaceutical company focused on the discovery
and development of innovative medicines targeting microRNAs
(the "Company" or "Regulus"), today announced
that Simos
Simeonidis, Ph.D., member of the Board of
Directors, has stepped down from the Board, due to the time
requirements of his recent appointment as co-Chief Executive
Officer and co-Chief Investment Officer at Ally Bridge Group. His
resignation was effective December 6,
2022.
"On behalf of the Board and the whole team at Regulus, I would
like to thank Simos for his impactful leadership during his tenure
at Regulus," said Stelios Papadopoulos, Ph.D., Chairman of the
Board of Directors of Regulus. "Since joining the Board, Simos,
with his expertise in investment management and biomedical
research, has provided the team with invaluable insights that have
helped Regulus achieve milestones and position the company for
long-term success."
"Simos has been a valuable member of our team and we have
appreciated his experience, dedication and thoughtful guidance as a
Board member," said Jay Hagan,
President and Chief Executive Officer of Regulus Therapeutics. "We
appreciate his service and commitment to Regulus and wish him all
the best in his future endeavors."
"It has been my pleasure to work with the Regulus management
team in advancing the clinical development of RGLS8429," said Dr.
Simeonidis. "I look forward to seeing the company continue its
progress and deliver on novel targeted microRNA-based therapies for
the treatment of ADPKD."
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a
biopharmaceutical company focused on the discovery and development
of innovative medicines targeting microRNAs. Regulus has leveraged
its oligonucleotide drug discovery and development expertise to
develop a pipeline complemented by a rich intellectual property
estate in the microRNA field. Regulus maintains its corporate
headquarters in San Diego, CA.
Forward-Looking Statements
Statements contained in this presentation regarding matters that
are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements associated with the Company's RGLS8429
program, including the expected timing and future occurrence of
other preclinical and clinical activities. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Regulus' current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks associated
with the process of discovering, developing and commercializing
drugs that are safe and effective for use as human therapeutics and
in the endeavor of building a business around such drugs, and the
risk additional toxicology data may be negative. In addition, while
Regulus expects the COVID-19 pandemic to adversely affect its
business operations and financial results, the extent of the impact
on Regulus' ability to achieve its preclinical and clinical
development objectives and the value of and market for its common
stock, will depend on future developments that are highly uncertain
and cannot be predicted with confidence at this time, such as the
ultimate duration of the pandemic, travel restrictions,
quarantines, social distancing and business closure requirements in
the U.S. and in other countries, and the effectiveness of actions
taken globally to contain and treat the disease. These and other
risks are described in additional detail in Regulus' filings with
the Securities and Exchange Commission, including under the "Risk
Factors" heading of Regulus most recently quarterly report on Form
10-Q. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Regulus
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-resignation-of-board-member-301699963.html
SOURCE Regulus Therapeutics Inc.